Lisa Schimanski
Overview
Explore the profile of Lisa Schimanski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
764
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Richardson E, Bibi S, McLean F, Schimanski L, Rijal P, Ghraichy M, et al.
Front Immunol
. 2024 Jul;
15:1383753.
PMID: 39040106
Outbreaks of Ebolaviruses, such as Sudanvirus (SUDV) in Uganda in 2022, demonstrate that species other than the Zaire ebolavirus (EBOV), which is currently the sole virus represented in current licensed...
2.
Donnellan F, Rayaprolu V, Rijal P, ODowd V, Parvate A, Callaway H, et al.
bioRxiv
. 2024 Jul;
PMID: 38979279
Ebolavirus disease (EVD) is caused by multiple species of . Monoclonal antibodies (mAbs) against the virus glycoprotein (GP) are the only class of therapeutic approved for treatment of EVD caused...
3.
Chen X, Mohapatra A, Nguyen H, Schimanski L, Tan T, Rijal P, et al.
PLoS Pathog
. 2024 Jun;
20(6):e1012246.
PMID: 38857264
Antibody-mediated immunity plays a key role in protection against SARS-CoV-2. We characterized B-cell-derived anti-SARS-CoV-2 RBD antibody repertoires from vaccinated and infected individuals and elucidate the mechanism of action of broadly...
4.
Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2
Huang K, Chen X, Mohapatra A, Nguyen H, Schimanski L, Tan T, et al.
Nat Commun
. 2023 Jan;
14(1):311.
PMID: 36658148
Antibody-mediated immunity plays a crucial role in protection against SARS-CoV-2 infection. We isolated a panel of neutralizing anti-receptor-binding domain (RBD) antibodies elicited upon natural infection and vaccination and showed that...
5.
Jeewandara C, Aberathna I, Pushpakumara P, Kamaladasa A, Guruge D, Wijesinghe A, et al.
Immunology
. 2022 Jun;
167(2):275-285.
PMID: 35758860
As there are limited data of the immunogenicity of the Sinopharm/BBIBP-CorV in different populations, antibody responses against different SARS-CoV-2 variants of concern and T cell responses, we investigated the immunogenicity...
6.
Jeewandara C, Aberathna I, Danasekara S, Gomes L, Fernando S, Guruge D, et al.
Immunology
. 2022 Jun;
167(2):263-274.
PMID: 35751563
To determine the antibody responses elicited by different vaccines against SARS-CoV-2, we compared antibody responses in individuals 3 months post-vaccination in those who had received different vaccines in Sri Lanka....
7.
Jayathilaka D, Jeewandara C, Gomes L, Jayadas T, Kamaladasa A, Somathilake G, et al.
Clin Exp Immunol
. 2022 May;
208(3):323-331.
PMID: 35641142
To characterize the IgG and IgA responses to different SARS-CoV-2 proteins, we investigated the antibody responses to SARS-CoV-2 following natural infection and following a single dose of AZD1222 (Covishield), in...
8.
Jeewandara C, Aberathna I, Pushpakumara P, Kamaladasa A, Guruge D, Wijesinghe A, et al.
Immun Inflamm Dis
. 2022 May;
10(6):e621.
PMID: 35634958
Background: To determine the kinetics and persistence of immune responses following the Sinopharm/BBIBP-CorV, we investigated immune responses in a cohort of Sri Lankan individuals. Methods: SARS-CoV-2 specific total antibodies were...
9.
Ertesvag N, Xiao J, Zhou F, Ljostveit S, Sandnes H, Lartey S, et al.
Commun Med (Lond)
. 2022 May;
2:36.
PMID: 35603265
Background: Evaluation of susceptibility to emerging SARS-CoV-2 variants of concern (VOC) requires rapid screening tests for neutralising antibodies which provide protection. Methods: Firstly, we developed a receptor-binding domain-specific haemagglutination test...
10.
Jeewandara C, Aberathna I, Gomes L, Pushpakumara P, Danasekara S, Guruge D, et al.
Immun Inflamm Dis
. 2022 Mar;
10(4):e592.
PMID: 35349749
Background: To understand the kinetics of immune responses with different dosing gaps of the AZD1222 vaccine, we compared antibody and T cell responses in two cohorts with two different dosing...